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Abstract
 
Activation of tumor-associated CD8
 
 
 
 cytotoxic T lymphocytes (CTLs) often requires antigen
representation, e.g., by dendritic cells (DCs), and CD4
 
 
 
 T cell help. Previously, we showed
that CTL-mediated tumor immunity required interleukin 4 (IL-4) during the immunization
but not effector phase. To determine the source and target cells of IL-4, we performed adop-
 
tive T cell transfers using CD4
 
 
 
 and CD8
 
 
 
 T cells from IL-4
 
 
 
/
 
 
 
 and IL-4R
 
 
 
/
 
 
 
 mice and an-
alyzed CTL generation. Even though necessary for CTL generation, CD4
 
 
 
 T cells did not
need to express IL-4 or IL-4R. Surprisingly, CTL generation required IL-4 but not IL-4R
expression by CD8
 
 
 
 T cells. As IL-4 (a) was expressed by naive CD8
 
 
 
 T cells within 24 h af-
ter antigen encounter, (b) IL-4 induced DC maturation, and (c) CTL development was im-
paired in T cell–reconstituted IL-4R
 
 
 
/
 
 
 
 mice, CD8
 
 
 
 T cell–derived IL-4 appears to act on
DCs. We conclude that CD4
 
 
 
 and CD8
 
 
 
 T cells provide different signals for DC activation
during CTL generation.
Key words: tumor vaccination • cytotoxic T lymphocytes • interleukin 4 • interleukin 4 
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Introduction
 
CTL responses to a variety of different antigens (e.g., viral-,
allo-, auto-, and tumor antigens) are induced by cross-
priming (1–4). For cross-priming, specialized APCs have to
take up and process cell-derived antigens and to present
MHC class I–restricted peptides to CD8
 
 
 
 T cells (5).
Cross-presenting APCs appear to be bone marrow–derived
(4), e.g., dendritic cells (DCs)
 
*
 
 (6, 7). CTL responses to
cell-derived antigens often depend on CD4
 
 
 
 T cell help
for which CD4
 
 
 
 and CD8
 
 
 
 T cells must recognize antigen
on the same APC (8, 9). In several models CD4
 
 
 
 T cell
help could be replaced by agonistic anti-CD40 antibodies
(10–12). The conclusion was that CD4
 
 
 
 T cells activate
APCs through CD40/CD40-ligand interactions, so that
APCs can activate CTLs.
Previously, we showed that IL-4
 
 
 
/
 
 
 
 mice have a defect
to develop systemic tumor immunity (13). This defect was
associated with impaired CTL and Th1 responses. Applica-
tion of exogenous IL-4 together with the cells used for im-
munization restored tumor immunity in IL-4
 
 
 
/
 
 
 
 mice, rul-
ing out a developmental defect and pointing to the priming
phase during which IL-4 is required. This was firmly estab-
lished by antibody neutralization of IL-4 in normal mice,
showing that anti-IL-4 antibodies abolished tumor immu-
nity when given at the time of immunization but not when
given at the time of tumor challenge (13). The question
which cells have to produce and respond to IL-4 for CTL
generation remained open and was addressed here focusing
on cells involved in the above mentioned three cell type
interactions (CD4
 
 
 
, CD8
 
 
 
 T cells, and APCs).
IL-4 is mainly produced by CD4
 
 
 
 T cells (Th2 cells)
(14) which are associated with humoral immune responses
and counteract CTL development (15). Th2 cells are usu-
ally detected in the effector phase of an immune response,
e.g., after chronic antigen exposure (16), and after pro-
longed in vitro stimulation in the presence of exogenous
IL-4 (15, 16). In addition to CD4
 
 
 
 T cells, CD8
 
 
 
 T cells
were also shown to produce IL-4 after in vitro culture for a
longer period of time in the presence of exogenous IL-4
(17, 18). A functional role of IL-4 expressed by CD8
 
 
 
 T
cells in vivo is not known. DCs cultured in the presence of
IL-4 and GM-CSF had a more mature phenotype than
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those cultured with GM-CSF only (19–21). However, it
remained unclear whether IL-4 directly contributed to DC
maturation or suppressed the generation of other cells in
the culture such as macrophages (19).
CTL priming in T cell–reconstituted SCID mice has
been shown (22). By reconstituting SCID mice with T
cells from IL-4
 
 
 
/
 
 
 
 and IL-4R
 
 
 
/
 
 
 
 mice we created experi-
mental conditions so that defined cell types (e.g., CD4
 
 
 
and CD8
 
 
 
 T cells) could either produce or respond to
IL-4. We measured CTLs specific for a tumor rejection
antigen of the colon carcinoma CT26, an endogenous ret-
rovirus (23), because CTLs to antigens derived from CT26
cells have been shown to be induced by cross-priming (4,
24). We show that the generation of CTL responses to
the CT26-derived tumor antigen requires CD8
 
 
 
 T cell–
derived IL-4 which most likely acts on APCs.
 
Materials and Methods
 
Mice, Cell Lines, Immunizations, and Depletion of T Cell Sub-
sets.
 
BALB/c mice were purchased from Charles River. BALB/
c-SCID mice were obtained from The Jackson Laboratory and
Harlan Winkelmann GmbH. Recombination activating gene
(RAG)2-deficient (RAG2
 
 
 
/
 
 
 
) BALB/c mice were purchased
from Taconic. IL-4–deficient (IL-4
 
 
 
/
 
 
 
; reference 25), IL-4 re-
ceptor 
 
 
 
 chain–deficient (IL-4R
 
 
 
/
 
 
 
; reference 26), and RAG2
 
 
 
/
 
 
 
/
IL-4R
 
 
 
/
 
 
 
 double-knockout mice (all congenic to BALB/c) were
bred at the animal facilities of our institutions. C57Bl/6 OT-I
mice express a transgenic T cell receptor specific for the H2-K
 
b
 
–
restricted peptide ova
 
257–264
 
 derived from chicken ovalbumin (27)
and were provided through M. Zenke (MDC Berlin, Berlin,
Germany) with kind permission of F. Carbone and W. Heath.
OT-I mice were crossed to Rag1
 
 
 
/
 
 
 
 mice obtained from The
Jackson Laboratory and RAG1-deficient OT-I mice (OT-I 
 
 
 
RAG1
 
 
 
/
 
 
 
) were used for the experiments. CT26 is a BALB/c
colon carcinoma expressing MHC class I but not MHC class II
molecules as determined by cytofluorimetric analysis (data not
shown). Renca is a BALB/c renal cell carcinoma cell line. All cell
lines were cultured in RPMI-1640 with 10% FCS. For the analy-
sis of tumor immunity, mice were subcutaneously injected with
10
 
6
 
 irradiated (100 Gy) CT26 cells and 2 wk later contralaterally
challenged with 10
 
6
 
 viable tumor cells. Mice that had not devel-
oped a tumor within 60 d were scored as tumor free. For deple-
tion of CD4
 
 
 
 and CD8
 
 
 
 T cells, immunized BALB/c mice re-
ceived a single intraperitoneal injection of 100 
 
 
 
g anti-CD4
(GK1.5) or anti-CD8 (2.43) antibody 2 d before challenge. De-
pletion of the respective T cell subpopulation was controlled by
cytofluorimetric analysis of peripheral blood using Coulter
EPICS-XL (Beckman Coulter) and anti-CD4-PE (RM4–5) and
anti-CD8
 
 
 
-FITC (53–6.7; BD PharMingen).
 
Adoptive Transfer of T Lymphocytes and Cytotoxicity Assays.
 
Single cell suspensions of splenocytes were prepared and red
blood cells were removed by NH
 
4
 
Cl treatment. For positive se-
lection of CD4
 
 
 
 or CD8
 
 
 
 T cells, splenocytes were incubated
with microbeads specific for CD4 or CD8
 
 
 
 (Miltenyi Biotec),
respectively, and passed over a MACS column according to the
manufacturer’s recommendations. For removal of contaminating
adherent cells, enriched CD4
 
 
 
 and CD8
 
 
 
 T cells were incubated
in Petri dishes for 30 min at 37
 
 
 
C. The purity of each preparation
was analyzed by cytofluorimetric analysis as described above and
was 93–99%. Before intravenous injection into the tail vein of
 
immunodeficient mice, T cells were washed twice and resus-
pended in PBS. Each recipient received 2 
 
 
 
 10
 
7
 
 CD4
 
 
 
 and 10
 
7
 
CD8
 
 
 
 T cells in a total volume of 200 
 
 
 
l. All experimental
groups consisted of 3–5 mice.
For induction of CTLs, mice were immunized twice with 10
 
6
 
irradiated (100 Gy) CT26 cells in a 2-wk interval. 7–10 d after
the second immunization, single-cell suspensions of red blood
cell–depleted spleen cells were prepared. To evaluate reconstitu-
tion efficacy, spleen cells from mice of one experimental group
were pooled, counted, and the percentage of CD4
 
 
 
 and CD8
 
 
 
 T
cells was determined by cytofluorimetric analysis as described
above. Splenocytes were cultured at 2 
 
 
 
 10
 
6
 
/ml in RPMI-1640
plus 10% FCS, penicillin/streptomycin, MEM, and 2-ME (50
 
 
 
M) in the presence of 100 ng/ml of the H2-L
 
d
 
–restricted pep-
tide AH1 (SPSYVYHQF) which is derived from an activated en-
dogenous retrovirus in CT26 cells (23). After 6–7 d of culture,
responder cells were harvested, washed twice and incubated with
 
51
 
Cr (1 mCi/ml) (NEN Life Science Products)-labeled target
cells at different E/T cell ratios. After an incubation period of
4.5 h, supernatants were assayed for radioactivity on a gamma
counter (Top count; Packard Instrument Co.). The percent lysis
was calculated as [(sample cpm 
 
 
 
 spontaneous cpm)/(maximal
cpm 
 
 
 
 spontaneous cpm)] 
 
 
 
 100%. Spontaneous release was be-
low 22% in all experiments. CT26-specific lysis represents the
difference between the percent lysis of CT26 cells and the per-
cent lysis of Renca cells. AH1-specific lysis represents the differ-
ence between percent lysis of Renca cells loaded with 1 
 
 
 
g/ml of
AH1 and Renca cells loaded with the same amount of the H2-
L
 
d
 
–restricted, 
 
 
 
-galactosidase–derived peptide TPHPARIGL.
Due to elevated levels of NK cell activity in SCID mice, lysis of
Renca cells varied in the course of the experiments between 12–
48%. CT26-specific lysis and the corresponding AH1-specific ly-
sis are only shown if the difference between the percent lysis of
CT26 cells and the percent lysis of Renca cells was at least 40%
(at an E/T ratio of 10:1).
 
Stimulation of OT-I 
 
 
 
 RAG1
 
 
 
/
 
 
 
 Splenocytes and Detection of
IL-4 mRNA by Quantitative Reverse Transcription PCR.
 
Single
cell suspensions of red blood cell-depleted splenocytes from
OT-I 
 
 
 
 RAG1
 
 
 
/
 
 
 
 mice were cultured in RPMI-1640
 
 
 
plus 10%
FCS, penicillin/streptomycin, MEM, and 2-ME (50 
 
 
 
M) at 1.5 
 
 
 
10
 
6
 
/ml in the presence or absence of 5 
 
 
 
g/ml peptide ova
 
257–264
 
(SIINFEKL). Cells were then harvested and total RNA was ex-
tracted using the Invisorb Spin Cell RNA Kit (Invitek) according
to the manufacturer’s instructions. Quantitative reverse transcrip-
tion (RT)-PCR was performed using an ABI PRISM 7700 de-
tection system and software (PerkinElmer). Primer and probe se-
quences for HPRT and IL-4 were used as published (28): HPRT
sense 5
 
 
 
-CTGGTGAAAAGGACCTCTCG-3
 
 
 
, HPRT antisense
5
 
 
 
-TGAAGTACTCATTATAGTCAAGGGCA-3
 
 
 
, HPRT probe
JOE-5
 
 
 
-TGTTGGATACAGGCCAGACTTTGTTGGAT-3
 
 
 
-
6-carboxytetramethylrhodamine (Tamra); IL-4 sense 5
 
 
 
-AGAT-
CATCGGCATTTTGAACG-3
 
 
 
, IL-4 antisense 5
 
 
 
-TTTGG-
CACATCCATCTCCG-3
 
 
 
, IL-4 probe 6-carboxyfluorescein
(FAM)-5 -TCACAGGAGAAGGGACGCCATGC-3 -Tamra.
The IL-4 primers were intron spanning. Therefore, amplification
as a result of DNA contamination could be excluded. Cycling
conditions were 20 min at 48 C (cDNA Synthesis), 10 min at
95 C, followed by 40 repeats of 95 C for 15 s and 60 C for 1
min. RNA from J558L, J558L transfected with the IL-4 gene
(J558L-IL-4), and RNA from unstimulated lymphocytes estab-
lished specificity of primer pairs and probes and were used for
standard curves. RNA samples in the absence of reverse tran-
scriptase were included in all experiments and did not give PCR1769 Schüler et al.
signals excluding contamination with genomic DNA. IL-4 and
HPRT transcripts were analyzed in one reaction (multiplex anal-
ysis). IL-4 transcripts were normalized to HPRT abundance.
 Rn is determined by the sequence detector software as:  Rn  
(Rn )   (Rn ), where Rn    emission intensity of reporter/
emission intensity of quencher at any given time in a reaction
tube, and Rn    emission intensity of reporter/emission inten-
sity of quencher before PCR amplification in that same reaction
tube.
Generation of DCs, Coculture with IL-4, and FACS® Analysis.
Bone marrow cells were cultured at 2   106/ml in RPMI-1640
containing 10% FCS, penicillin/streptomycin, MEM, 2-ME (50
 M), and 10% supernatant from NIH cells transfected to secrete
murine GM-CSF (unpublished data). The final GM-CSF con-
centration was 10–20 ng/ml. At day 6, 50 ng/ml of recombi-
nant mouse IL-4 (BD PharMingen) were added. To prevent
maturation of DCs due to mechanical manipulation (29, 30),
cells were not replated. Instead, half of the medium was replaced
every second day. At day 12 of culture, DCs were harvested,
washed, and incubated in PBS containing 10% mouse serum and
2 mM EDTA for 20 min. This preincubation was followed by
the addition of monoclonal antibodies against mouse CD11c
(HL3), I-Ad/I-Ed (2G9), B7.2 (GL1), and CD40 (HM-40–3; all
BD PharMingen). Cytofluorimetric analysis was performed as
described above.
Results
CD4  T Cell–dependent, CTL-mediated Tumor Immunity
Is Impaired in IL-4 /  and IL-4R /  Mice. First, we ana-
lyzed whether IL-4R /  mice have a similar phenotype as
IL-4 /  mice with regard to the generation of tumor im-
munity. Both knockout strains were generated with
BALB/c ES cells and can therefore be considered as con-
genic BALB/c lines (25, 26), thus minimizing the problem
of unwanted alloresponses. Immunization with irradiated
cells of the BALB/c colon carcinoma CT26 protected 80%
of wild-type (wt) mice but only 33% of IL-4 /  and IL-
4R /  mice from a lethal tumor challenge showing that
IL-4 /  and IL-4R /  mice are similarly impaired to de-
velop tumor immunity (Fig. 1 a). To analyze which T cell
subset was required in the effector phase, wt mice were im-
munized as before and depleted of either CD4  or CD8 
T cells beginning 2 d before challenge with CT26 cells.
CD4  T cells were not required as effector cells for tumor
rejection in this model, whereas CD8  T cells were essen-
tial (Fig. 1 b). In addition to the capability of CD8  T cells
to mediate rejection of CT26 tumors in vivo, CTLs de-
rived from immunized wt mice specifically lysed CT26
cells after 1 wk of in vitro restimulation with the CT26-
derived peptide AH1 (Fig. 1 c). Intracellular cytokine stain-
ing showed that CT26-reactive CTLs secreted IFN-  but not
IL-4 (data not shown), indicating that conventional CTLs
were involved in tumor cell destruction. Next we tested,
whether CD4  T cells contribute to CTL generation in T
cell–reconstituted SCID mice, as we wanted to use this sys-
tem for subsequent experiments to analyze the role of IL-4
for CTL generation. SCID mice were reconstituted with
CD4  and CD8  T cells or CD8  T cells alone, immu-
nized with CT26 cells and subsequently analyzed for CTL
activity. Mice reconstituted with both T cell subsets con-
tained CTLs after immunization, whereas no CTL activity
could be detected in mice reconstituted only with CD8  T
cells (Fig. 1 d). Therefore, CTL activation to CT26 cells
(MHC class I , class II ) requires help from CD4  T cells,
which thus have to recognize tumor-derived antigens on
MHC class II  APCs. As CTL generation against CT26-
derived antigens requires cross-presentation by host APCs
(4, 24), it is likely that CD4  T cell–dependent CTL prim-
Figure 1. CD4  T cell–dependent, CTL-mediated tumor immunity is
impaired in IL-4 /  and IL-4R /  mice. (a) The indicated mice (5–6/
group) were immunized with 106 irradiated CT26 cells, contralaterally
challenged with 106 viable CT26 cells 2 wk later, and tumor growth was
monitored. One out of three experiments with similar results is shown.
(b) BALB/c mice (10/group) were immunized and challenged with
CT26 as described in panel a and tumor growth was monitored. 2 d be-
fore challenge, mice were depleted of CD4  or CD8  T cells. For a and
b, the percentage of tumor free mice 60 d after challenge is shown. (c) To
determine tumor-specific CTL activity in vitro, BALB/c mice (five/
group) were immunized twice with 106 irradiated CT26 cells in a 2-wk
interval or left untreated. 7 to 10 d after the second immunization, spleen
cells were restimulated for 7 d with the CT26-derived peptide AH1.
CTL activity against CT26 was determined for immunized (diamonds)
and nonimmunized BALB/c mice (triangles) at different E:T ratios. One
representative experiment out of three is shown. (d) To test whether the
generation of anti-CT26 CTLs was CD4  T cell dependent, SCID mice
(four/group) were reconstituted with either sorted BALB/c CD4  and
CD8  T cells or CD8  T cells only. Recipients were immunized or left
untreated and analyzed for CTL activity as described in c. CTL activities
of immunized CD4wt/CD8wt-recipients (squares), immunized CD8wt-
recipients (triangles), and nonimmunized CD4wt/CD8wt-recipients (cir-
cles) was measured against CT26.1770 CTL Generation Requires IL-4 from CD8  T Cells
ing in our model also required both T cell subsets to inter-
act with the same APC as described previously in other ex-
perimental systems (8, 9).
CTL Generation Does Not Require IL-4 or IL-4R Expres-
sion by CD4  T Cells. Having demonstrated that CTLs
against CT26 can be primed in T cell–reconstituted SCID
mice, we next transferred combinations of purified CD4 
or CD8  T cells that were selectively defective for IL-4 or
IL-4R expression. We analyzed first, whether CD4  T
cell–derived IL-4 was necessary for the generation of
CTLs. SCID mice were reconstituted with CD4  T cells
from IL-4 /  mice (CD4IL-4 / ) and CD8  T cells from
wt mice (CD8wt) and immunized with CT26 cells. Control
mice received CD4wt and CD8wt cells and were immu-
nized or left untreated. Spleen cells from nonimmunized
mice showed no cytotoxicity. In contrast, spleen cells from
immunized CD4wt/CD8wt and CD4IL-4 / /CD8wt recipi-
ents specifically lysed CT26 cells (Fig. 2 a) and Renca cells
pulsed with AH1 peptide (Fig. 2 c). This experiment ex-
cluded CD4  T cells as the critical source of IL-4, although
CD4  T helper cell function could require IL-4 from an-
other cell type. To analyze this, we used CD4  T cells
from IL-4R /  mice (CD4IL-4R / ) and CD8wt cells to
reconstitute SCID mice. Splenocytes from immunized
CD4IL-4R / /CD8wt and CD4wt/CD8wt recipients but not
from nonimmunized CD4wt/CD8wt mice showed specific
cytotoxicity (Fig. 2, b and d). Therefore, while CTL gen-
eration was dependent on CD4  T cell help (Fig. 1 d), this
help was not associated with the production or consump-
tion of IL-4 by CD4  T cells.
IL-4 but Not IL-4R Expression by CD8  T Cells Is Re-
quired for CTL Generation. To investigate whether the
generation of CTLs required CD8  T cells to produce
IL-4, SCID mice were reconstituted with CD8IL-4 /  and
CD4wt cells and CTL activity was determined as above.
Remarkably, CTLs could not be detected in CD4wt/
CD8IL-4 / -recipients, while spleen cells from immunized
CD4wt/CD8wt-controls specifically lysed target cells (Fig. 3,
Figure 2. The generation of CT26-specific CTLs does not require IL-4-
or IL-4R-expression by CD4  T cells. SCID mice were reconstituted
with sorted CD8  T cells from wt mice and sorted CD4  T cells from wt,
IL-4 /  or IL-4R /  mice, respectively. Immunizations and in vitro re-
stimulation of spleen cells were done as described in Fig. 1. CT26-specific
(a and b) and AH1-specific CTL activity (c and d) of CD4IL-4 / /CD8wt-
( ) (a and c), CD4IL-4R / /CD8wt- ( ) (b and d), and CD4wt/CD8wt-
recipients ( ) (a–d) was measured at various E:T ratios. Percent specific
lysis represents the difference between percent lysis of CT26 cells and Renca
cells (a and b) or the difference between percent lysis of AH1 peptide-loaded
and control peptide loaded Renca cells (c and d). Splenocytes from nonim-
munized CD4wt/CD8wt-recipients served as negative control ( ).
Figure 3. IL-4- but not IL-4R-expression by CD8  T cells is required
for the generation of CT26-specific CTLs. SCID mice were reconstituted
with sorted CD4  T cells from wt mice and sorted CD8  T cells from wt,
IL-4 / , or IL-4R /  mice, respectively. Recipients were immunized
with CT26 and CT26-specific (a and b) as well as AH1-specific CTL ac-
tivity (c and d) of CD4wt/CD8IL-4 / - ( ) (a and c), CD4wt/CD8IL-4R / -
( ) (b and d), and CD4wt/CD8wt-recipients ( ) (a–d) was determined as
described in Fig. 2. Splenocytes from nonimmunized CD4wt/CD8wt-recip-
ients served as negative control ( ). The same controls are shown in a and
Fig. 2 a and in c and d because these experiments were done in parallel.1771 Schüler et al.
a and c). Next we analyzed, whether CD8  T cell–derived
IL-4 acted in an autocrine or paracrine fashion. We
cotransferred CD8IL-4R /  and CD4wt cells to SCID mice
and determined CTL activity after immunization with
CT26 cells. Splenocytes of CD4wt/CD8IL-4R / -recipients
showed specific lysis, although it was slightly reduced com-
pared with splenocytes from CD4wt/CD8wt-control mice
(Fig. 3, b and d). These results demonstrate that CTL acti-
vation required IL-4 from CD8  T cells which acted pri-
marily in a paracrine fashion.
Naive CD8  T Cells Upregulate IL-4 mRNA within 24 h
of Antigen Stimulation. Due to the low precursor fre-
quency of AH1-specific CD8  T cells, we used T cell re-
ceptor transgenic OT-I mice (27) to determine whether
naive CD8  T cells can express IL-4 in response to primary
antigen-encounter. To exclude IL-4 expression from
CD4  T cells, spleen cells from RAG1-deficient OT-I
mice (OT-I   RAG1 / ) were cultured with or without
their cognate, ovalbumin-derived peptide ova257–265 (SIIN-
FEKL). 24 h later, IL-4 mRNA levels were determined by
quantitative RT-PCR. Cycle threshold analysis revealed
linear amplification of IL-4 mRNA in peptide stimulated
splenocytes, while mRNA levels from nonstimulated sple-
nocytes never attained linear amplification (Fig. 4 a).
HPRT gene expression analyzed in parallel showed a simi-
lar amplification profile with or without peptide stimula-
tion (Fig. 4 b). We therefore conclude that there is little, if
any, IL-4 mRNA in unstimulated splenocytes, while IL-4
mRNA is induced upon antigenic stimulation of CD8 
OT-I cells. Thus, naive CD8  T cells express IL-4 within
24 h after antigenic stimulation. This finding correlates
with the failure to generate CTLs after adoptive transfer of
CD8IL-4 /  cells (Fig. 3 a) and suggests that IL-4 produc-
tion by classical CD8  T cells can contribute to CTL gen-
eration. However, IL-4-expression by AH1-specific CD8 
T cells remains to be shown.
IL-4 Is a Maturation Factor for Immature DCs. In our ex-
perimental system, DCs were the likely APCs, as (a) the re-
cipient mice lacked B cells and (b) macrophages are less ef-
ficient in CTL cross-priming compared with DCs (31–33).
To test whether IL-4 directly activates DCs, bone marrow
cells from IL-4R /  and IL-4R /  mice were cultured for
6 d in the presence of GM-CSF, when the majority of
nonadherent cells were immature DCs (low MHC class II,
low B7.2, low CD40). Subsequently, the cells were ex-
posed to IL-4 or left untreated and CD11c  cells were ana-
lyzed for the expression of MHC class II, B7.2, and CD40
(Fig. 5). IL-4–induced maturation of IL-4R /  DCs was
already visible 2 d after IL-4 exposure and is shown after a
6 d exposure time by the strong upregulation of MHC class
II, B7.2, and CD40 (Fig. 5, a, c, and e). Maturation of DCs
from IL-4R /  mice was not observed at this time (Fig. 5,
b, d, and f) ruling out that IL-4–unrelated stimuli, e.g.,
LPS, were responsible for the maturation of IL-4R / 
DCs. LPS induced similar activation of IL-4R /  and IL-
4R /  DCs demonstrating that DCs from IL-4R /  mice
are not generally defective to become activated (data not
shown). Although it has previously been demonstrated that
the addition of IL-4 to human peripheral blood mononu-
clear cells and murine bone marrow cells cultured with
GM-CSF results in the generation of DCs with enhanced
immunostimulatory capacity (19–21), our data show that
IL-4 induces maturation of differentiated immature DCs.
IL-4R Expression by Non-T, Non-B Cells Is Essential for
CTL Generation. The observations that CTL generation
did not require CD4  and CD8  T cells to express IL-4R
and that IL-4 activated immature DCs indicated a paracrine
effect of CD8  T cell–derived IL-4 on APCs during CTL
generation. To test this, CD4wt and CD8wt cells were trans-
ferred to RAG2 / /IL-4R /  or RAG2 / /IL-4R / 
mice. Both groups were immunized with CT26 cells and
analyzed for CT26-specific CTLs. As shown in Fig. 6,
CTL generation was strongly impaired in RAG2 / /IL-
4R /  mice, whereas CTL activity in RAG2 / /IL-4R / 
mice was comparable to that observed in the previous
experiments. These results indicate that host APCs require
Figure 4. Naive CD8  T cells upregulate IL-4 gene expression within
24 h of antigen stimulation. Spleen cells from OT-I   RAG1 /  mice
were incubated for 24 h in the presence ( ) or absence ( ) of 5  g/ml
peptide ova257–264 (SIINFEKL) and the production of IL-4 mRNA was
evaluated by quantitative RT-PCR. Amplification plots for IL-4 (a) and
hypoxanthine guanine phosphoribosyltransferase (HPRT) (b) are shown
for each RNA sample, in triplicates. IL-4 transcripts were normalized to
HPRT abundance and analyzed in one reaction (multiplex analysis). One
representative out of three experiments is shown.  Rn represents changes
of emission of reporter dye versus quenching dye over the course of the
PCR reaction.1772 CTL Generation Requires IL-4 from CD8  T Cells
IL-4R expression to activate CTLs. Additionally, these data
support that CTLs to CT26-derived antigens are induced
by cross-priming (4, 24) as direct priming should have oc-
curred independently of IL-4R expression on host cells.
It should be noted that T cell recovery from the recon-
stituted mice in the above experiments was similar regard-
less of the phenotype of the donor T cells or recipient
mice. In Table I, the numbers of recovered splenocytes
from reconstituted mice and the percentage of CD4  and
CD8  T cells for each experimental situation are shown.
Thus, differences in CTL generation did not result from
different reconstitution efficacy.
Discussion
Previously we showed that CTL- and Th1-associated tu-
mor immunity required IL-4 during the priming phase
(13). Here we demonstrated that the generation of CTL
responses to a tumor-derived antigen (the peptide AH1 de-
rived from an endogenous retrovirus activated in CT-26
cells) required CD8  T cells to produce IL-4 which most
likely acted on APCs. The data (summarized in Table II)
are discussed with regard to the dual role which IL-4 can
Figure 5. IL-4 induces maturation of
DCs. Day 6 bone marrow–derived DCs
from BALB/c (a, c, and e) and IL-4R / 
mice (b, d, and f) were either treated with
50 ng/ml recombinant mouse IL-4 (red
lines) or left untreated (green lines). 6 d later,
CD11c  cells were analyzed for the expres-
sion of MHC class II (a and b), B7.2 (c and
d) and CD40 (e and f). Isotype-matched
controls are shown in blue. One representa-
tive out of two experiments is shown.
Figure 6. IL-4R-expression by non-T, non-B cells is required for the
generation of CT26-specific CTLs. CD4  and CD8  T cells from wt
mice were transferred to RAG2 / /IL-4R /  ( ) and RAG2 / /IL-
4R /  mice ( ). The recipients were immunized with CT26 and CT26-
specific (a) as well as AH1-specific CTL activity (b) was determined as de-
scribed in Fig. 2. Splenocytes from reconstituted, nonimmunized
RAG2 / /IL-4R /  recipients served as negative control ( ).1773 Schüler et al.
play during T cell-responses and the possible regulatory
role of CD8  T cells producing IL-4 during cross-priming.
The Dual Role of IL-4. There is good evidence that IL-4
produced by CD4  T cells (Th2 cells) has adverse effects
on cellular immune responses, e.g., counteracts Th1-devel-
opment or CTL-responses (15). The requirement of IL-4
for CTL generation appears to be in disagreement with the
opposing effects of Th2 cells on CTL development. This
apparent discrepancy can be resolved, however, if one con-
siders that (a) in our model, CTL responses did not require
CD4  T cells to produce or respond to IL-4 and (b) Th2
cells are usually detected late in immune responses, long af-
ter T cell priming has occurred, e.g., after prolonged anti-
gen exposure in vivo (16) or after in vitro activation of
CD4  T cells in the presence of exogenous IL-4 (15, 16).
Late IL-4 derived from CD4  T cells stands in contrast to
early IL-4 which supports CTL generation. We showed
previously by IL-4 neutralization in normal mice that the
generation of tumor immunity required IL-4 in the prim-
ing phase only, e.g., at the time of immunization. In the ef-
fector phase, e.g., at the time of tumor challenge, IL-4 was
not needed (13). In the current study we showed that not
only the time point but also the cellular source of IL-4 is
important for CTL generation. Thus, our results reveal a
defined function for IL-4–producing CD8  T cells in vivo.
It is known that CD8  T cells can produce IL-4 (Tc2 cells)
after exposure to IL-4 in vitro (17, 18). Because CTLs
against CT26 produced IFN-  but no detectable IL-4 (data
not shown) and IL-4 was dispensable in the effector phase,
it appears that the early IL-4 from CD8  T cells was neces-
sary for the generation of typical CTLs. This assumption is
supported by the observation that CTL generation did not
require IL-4R expression by CD8  T cells which probably
would have been necessary for the development of Tc2
cells. Correlating with the requirement for CD8  T cell–
derived IL-4 for CTL generation in vivo, quantitative RT-
PCR analysis showed that naive CD8  OT-I cells, similar
to naive CD4  T cells (28, 34), can upregulate IL-4 gene
expression within 24 h after T cell receptor stimulation in
vitro. It is therefore likely that IL-4 produced by CD8  T
cells in the priming phase of the antitumor response con-
tributed to CTL generation. IL-4 from CD4  T cells could
not substitute for CD8  T cell–derived IL-4, although
CD4  T cells were essential for CTL generation during the
priming phase. Several findings suggest that APCs have to
respond to IL-4 during CTL generation: (a) CD4  and
CD8  T cells did not need to express IL-4R, (b) IL-4 in-
duced expression of MHC class II, B7.2, and CD40 by im-
mature DCs, and (c) CTLs did not develop in T cell–
reconstituted IL-4 R /  recipient mice. Additionally, IL-4
Table I. Recovery of Transferred T Cells Is Similar Regardless of the T Cell or Recipient Phenotype
Transferred T cells Splenocytes recovered
CD4  CD8  Recipients Immunization Percent CD4  Percent CD8  Cell number
wt wt SCID   9.9 5.1 8.9   107
wt wt SCID   18.0 9.4 10.5   107
IL-4 /  wt SCID   22.0 9.5 9.6   107
IL-4R /  wt SCID   13.2 13.3 10.1   107
wt IL-4 /  SCID   16.3 10.5 13.5   107
wt IL-4R /  SCID   16.3 9.8 11.3   107
wt wt RAG2 / /IL-4R /   18.9 9.0 8.3   107
wt wt RAG2 / /IL-4R /    19.1 7.0 8.1   107
wt wt RAG2 / /IL-4R /    18.2 9.2 5.5   107
Lymphocyte-deficient mice were reconstituted with CD4  and CD8  T cells from the indicated donors and were left untreated or subsequently
immunized with CT26 cells as described in Materials and Methods. 10 d after the second immunization, splenocytes from five recipients per group
were pooled and counted. The percentage of CD4  and CD8  T cells was determined by cytofluorimetric analysis. The data shown for SCID and
RAG2 /  mice, respectively, represent one experiment in which the indicated T lymphocyte combinations were transferred in parallel. The lower
percentage of CD4  and CD8  T cells in nonimmunized compared to immunized SCID mice was not observed in five further experiments.
Table II. Summary of Results
Transferred T cells
CD4  CD8  Recipients na Lysis
wt wt IL-4R /  6 Yes
  wt IL-4R /  2N o
IL-4 /  wt IL-4R /  2 Yes
IL-4R /  wt IL-4R /  4 Yes
wt IL-4 /  IL-4R /  2N o
wt IL-4R /  IL-4R /  3 Yes
wt wt IL-4R /  3N o
an represents the number of independent experiments performed with
groups of 3–5 immunized recipient mice.1774 CTL Generation Requires IL-4 from CD8  T Cells
overexpression in mice increases rather than decreases
IFN-  (35, 36) and IL-12 production (37) and IL-4 in-
duces IL-12 expression by DCs (37). The latter finding
has been explained by a negative feedback mechanism
counteracting Th2 responses. An alternative explanation
is that early IL-4 production by CD8  T cells, in contrast
to the central role of late IL-4 from CD4  T cells during
Th2 responses, is necessary for Th1 responses to certain
antigens. Both, impaired Th1 responses in IL-4 /  mice
(13, 38, 39) and the observation that CD8  T cells acti-
vate DCs in vivo (40) support this assumption. However,
we cannot yet exclude other target cells that respond to
IL-4 and contribute to the generation of antitumor
CTLs.
A Regulatory Role of IL-4–producing CD8  T Cells during
Cross-priming. IL-4 /  mice mount normal CTL re-
sponses against viruses (41) that directly activate APCs
(40), suggesting that cytokine-mediated amplification sig-
nals are particularly required for the generation of im-
mune responses against weak antigens, e.g. tumor or
autoantigens, in order to allow DC activation and subse-
quent T cell priming. CTLs to antigens derived from
CT26 cells have been shown to be induced by cross-
priming (4, 24). This is supported here, because direct
CTL activation by CT-26 cells used for immunization
should have occurred in IL-4R /  recipient mice recon-
stituted with CD4wt/CD8wt T cells. During cross-prim-
ing, CD4  T cells activate APCs that present exogenous
(cell-derived) antigens to both CD4  T helper cells and
CD8  CTLs (8, 9). The data presented here suggest that
CTL generation requires CD4  and CD8  T cells to pro-
vide qualitatively different signals to APCs. In this model,
CD8  T cells produce IL-4 and most likely induce the
maturation of DCs. In response to IL-4, DCs produce a
chemokine that attracts naive CD4  T cells (42) which
may provide another signal to APCs that is unrelated to
IL-4. Only both signals together ensure CTL generation.
Together, the data presented here suggest an as yet unap-
preciated regulatory function for CD8  T cells in the
priming phase of CD4  T cell–dependent, CTL-medi-
ated antitumor immune responses. Whether APCs receive
the primary activation signal from CD4  or CD8  T cells
cannot be decided from this study. However, parallel ex-
periments suggest that CD8  T cell/APC interactions
precede those between CD4  T cells and APCs (unpub-
lished data).
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